|Brand name(s), other common name(s)||Rydapt®|
|Drug type||Kinase inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Rydapt is FDA approved for the treatment of adult patients with:
- Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Limitations of Use:
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
- Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Side effects needing medical attention
- AML: The most common adverse reactions were a fever in a patient with neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, nose bleed, device-related infection, hyperglycemia (high blood sugar), and upper respiratory tract infection.
- ASM, SM-AHN, or MCL: The most common adverse reactions were nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, fever, headache, and difficulty breathing.
Warning: Monitor for symptoms of interstitial lung disease or pneumonitis. Discontinue Rydapt in patients with signs or symptoms of pulmonary toxicity.